Your shopping cart is empty

Subscriber login

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

Check out our free and informative ezines and sign up now

Home > Newsletters > Drug Industry Daily > Safety Could Separate Actelion’s PAH Drug From the Pack, Analyst Says

Drug Industry Daily

May 1, 2012 | Vol. 11 No. 86

Safety Could Separate Actelion’s PAH Drug From the Pack, Analyst Says

Actelion is looking to submit regulatory filings for its pulmonary arterial hypertension (PAH) drug macitentan in the fourth quarter after hitting its endpoint in a pivotal trial.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
Email This Article
RSS
Free Trial
Archives
Sample PDF

Lilly Phase III Non-Hodgkin’s Lymphoma Drug Trial Halted House Track-and-Trace Bill Moves to Floor Without Unit-Level Designs Lawmakers Say Patients Deserve to Know if Their Drugs Contain Gluten Boehringer Ingelheim’s NSCLC Candidates Get Mixed Results

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.